MNT 001
Alternative Names: MNT-001Latest Information Update: 29 Apr 2024
At a glance
- Originator Minotaur Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 15 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Apr 2024 MNT 001 is available for licensing as of 18 Apr 2024. https://minotaurtherapeutics.com/?page_id=87 (Minotaur Therapeutics pipeline, April 2024)
- 18 Apr 2024 Preclinical trials in Cancer in USA (Parenteral) as of April 2024 (Minotaur Therapeutics pipeline, April 2024)
- 18 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer released by Minotaur Therapeutics (Minotaur Therapeutics pipeline, April 2024) (QC feedback inc- LA info retained based on the col partner section which is "unpartnered" hinting at the comp willing to partner for dev)